More evidence needed to support BRAHMS copeptin test, says NICE in draft guidance
This article was originally published in Clinica
Executive Summary
A copeptin assay developed by Germany’s BRAHMS to help rule out myocardial infarction (MI) “shows potential” for being used routinely by the UK’s NHS. However, more evidence on its impact in clinical practice is required, concluded the National Institute for Health and Clinical Excellence (NICE) in draft guidance issued today for consultation.